Crispr Therapeutics shares tumble after significant earnings miss
Investing.com - Stevanato Group SpA (NYSE: STVN) reported first quarter EPS of €0.10, €0.01 better than the analyst estimate of €0.09. Revenue for the quarter came in at €256.6M versus the consensus estimate of €248.28M.
Guidance
Stevanato Group SpA sees FY 2025 EPS of €0.50-€0.54 versus the analyst consensus of €0.58.
Stevanato Group SpA sees FY 2025 revenue of €1.16B-€1.19B versus the analyst consensus of €1.33B.
Stevanato Group SpA’s stock price closed at €21.80. It is down -0.59% in the last 3 months and up 3.32% in the last 12 months.
Stevanato Group SpA saw 3 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Stevanato Group SpA’s stock price’s past reactions to earnings here.
According to InvestingPro, Stevanato Group SpA’s Financial Health score is "good performance".
Check out Stevanato Group SpA’s recent earnings performance, and Stevanato Group SpA’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar